title: Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism.
abstract: Based on our earlier work, a 2.5-fold increase in insulin secretion should completely inhibit hepatic glucose production through the hormone's direct effect on hepatic glycogen metabolism. The aim of the present study was to test the accuracy of this prediction and to confirm that gluconeogenic flux, as measured by three independent techniques, was unaffected by the increase in insulin. A 40-min basal period was followed by a 180-min experimental period in which an increase in insulin was induced, with euglycemia maintained by peripheral glucose infusion. Arterial and hepatic sinusoidal insulin levels increased from 10 +/- 2 to 19 +/- 3 and 20 +/- 4 to 45 +/- 5 microU/ml, respectively. Net hepatic glucose output decreased rapidly from 1.90 +/- 0.13 to 0.23 +/- 0.16 mg. kg(-1). min(-1). Three methods of measuring gluconeogenesis and glycogenolysis were used: 1) the hepatic arteriovenous difference technique (n = 8), 2) the [(14)C]phosphoenolpyruvate technique (n = 4), and 3) the (2)H(2)O technique (n = 4). The net hepatic glycogenolytic rate decreased from 1.72 +/- 0.20 to -0.28 +/- 0.15 mg. kg(-1). min(-1) (P < 0.05), whereas none of the above methods showed a significant change in hepatic gluconeogenic flux (rate of conversion of phosphoenolpyruvate to glucose-6-phosphate). These results indicate that liver glycogenolysis is acutely sensitive to small changes in plasma insulin, whereas gluconeogenic flux is not.
authors.affiliation: Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA. dale.edgerton@vanderbilt.com
authors.forename: D S
authors.initials: DS
authors.lastname: Edgerton
authors.forename: S
authors.initials: S
authors.lastname: Cardin
authors.forename: M
authors.initials: M
authors.lastname: Emshwiller
authors.forename: D
authors.initials: D
authors.lastname: Neal
authors.forename: V
authors.initials: V
authors.lastname: Chandramouli
authors.forename: W C
authors.initials: WC
authors.lastname: Schumann
authors.forename: B R
authors.initials: BR
authors.lastname: Landau
authors.forename: L
authors.initials: L
authors.lastname: Rossetti
authors.forename: A D
authors.initials: AD
authors.lastname: Cherrington
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D017666:Deuterium Oxide / Q000493:pharmacokinetics; D004285:Dogs; D005260:Female; D005934:Glucagon / Q000097:blood; D005943:Gluconeogenesis / Q000502:physiology*; D005947:Glucose / Q000378:metabolism*; D006946:Hyperinsulinism / Q000097:blood / Q000378:metabolism; D007328:Insulin / Q000097:blood / Q000502:physiology*; D007773:Lactates / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D008954:Models, Biological; D010728:Phosphoenolpyruvate / Q000378:metabolism; D011865:Radioisotope Dilution Technique
chemical_list: D001786:Blood Glucose; D002250:Carbon Radioisotopes; D007328:Insulin; D007773:Lactates; D008112:Liver Glycogen; D010728:Phosphoenolpyruvate; D005934:Glucagon; D005947:Glucose; D017666:Deuterium Oxide